These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32681007)

  • 41. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
    Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
    Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
    Vogelzang NJ
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
    Jacene H; Gomella L; Yu EY; Rohren EM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
    Sraieb M; Hirmas N; Conrad R; Marinova M; Essler M; Herrmann K; Ahmadzadehfar H
    Medicine (Baltimore); 2020 Sep; 99(38):e22287. PubMed ID: 32957385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dosing, administration, and safety of radium-223: How I do it.
    Dan TD; Doyle L; Raval AJ; Pridjian A; Gomella LG; Den RB
    Can J Urol; 2016 Jun; 23(3):8301-5. PubMed ID: 27347625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
    Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
    Coleman R; Brown J; Rathbone E; Flanagan L; Reid A; Kendall J; Howell S; Twelves C; Palmieri C; Anand A; MacPherson I; Brown S
    Trials; 2020 Jan; 21(1):89. PubMed ID: 31941523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-time scintigraphic assessment of intravenous radium-223 administration for quality control.
    Wright CL; Monk JP; Murrey DA; Hall NC
    Biomed Res Int; 2015; 2015():324708. PubMed ID: 25789312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
    Wilson JM; Parker C
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
    Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
    Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
    Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
    Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extraction of
    Großer OS; Wissel H; Wallbaum T; Genseke P; Kupitz D; Ricke J; Ruf J; Amthauer H
    Nuklearmedizin; 2017 Jun; 56(3):69-72. PubMed ID: 28383088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
    Suominen MI; Rissanen JP; Käkönen R; Fagerlund KM; Alhoniemi E; Mumberg D; Ziegelbauer K; Halleen JM; Käkönen SM; Scholz A
    J Natl Cancer Inst; 2013 Jun; 105(12):908-16. PubMed ID: 23682134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
    Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
    Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Chlorella as a Decorporation Agent to Enhance the Elimination of Radioactive Strontium from Body.
    Ogawa K; Fukuda T; Han J; Kitamura Y; Shiba K; Odani A
    PLoS One; 2016; 11(2):e0148080. PubMed ID: 26828430
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
    BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
    Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.